NASDAQ:CVAC CureVac B.V. Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding CureVac B.V. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $44.65 +0.85 (+1.94 %) (As of 09/25/2020 11:40 AM ET) Add Compare Share Today's Range$43.80Now: $44.65▼$45.8050-Day Range N/A52-Week Range$36.15Now: $44.65▼$85.00Volume6,092 shsAverage Volume1.91 million shsMarket Capitalization$7.86 billionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsChartCompetitorsHeadlinesSocial Media CureVac B.V., a clinical-stage biopharmaceutical company, engages in developing medicines based on messenger ribonucleic acid. The company's lead clinical programs include CV8102 that is in a Phase I clinical trial for the treatment of various types of solid tumors; and CV7202, which is investigating in a Phase I clinical trial for vaccination against rabies. It is also advancing mRNA vaccine program against coronavirus (SARS-CoV-2), which is in Phase I clinical trial. The company has collaboration and license agreements with GlaxoSmithKline Biologicals SA, Genmab B.V., Boehringer Ingelheim GmbH, and Eli Lilly and Company; development and option agreements with Arcturus Therapeutics, Inc., Acuitas Therapeutics Inc., and CRISPR Therapeutics AG; and a development and intellectual property agreement with Tesla Grohmann Automation GmbH. CureVac B.V. was founded in 2000 and is headquartered in Tübingen, Germany.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingCureVac B.V. has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $66.50, CureVac B.V. has a forecasted upside of 48.9% from its current price of $44.65.Amount of Analyst CoverageCureVac B.V. has only been the subject of 4 research reports in the past 90 days. Previous Next 2.1 Community Rank Outperform VotesCureVac B.V. has received 3 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCureVac B.V. has received 4 “underperform” votes. (Add your “underperform” vote.)Community SentimentCureVac B.V. has received 57.14% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about CureVac B.V. and other stocks. Vote “Outperform” if you believe CVAC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CVAC will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCureVac B.V. does not currently pay a dividend.Dividend GrowthCureVac B.V. does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CureVac B.V. insiders have not sold or bought any company stock. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for CureVac B.V. are expected to grow in the coming year, from ($2.84) to ($2.27) per share. Previous Next Analyst Opinion: 3.3Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.20 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CVAC Previous Symbol CUSIPN/A CIKN/A Webwww.curevac.com Phone49-70-71988-30Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares175,968,000Market Cap$7.86 billion Next Earnings DateN/A OptionableNot Optionable $44.65 +0.85 (+1.94 %) (As of 09/25/2020 11:40 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive CVAC News and Ratings via Email Sign-up to receive the latest news and ratings for CVAC and its competitors with MarketBeat's FREE daily newsletter. CureVac B.V. (NASDAQ:CVAC) Frequently Asked Questions Do Wall Street analysts recommend investors buy shares of CureVac B.V.? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CureVac B.V. in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for CureVac B.V.. What price target have analysts set for CVAC? 4 brokers have issued 12 month target prices for CureVac B.V.'s stock. Their forecasts range from $58.00 to $70.00. On average, they anticipate CureVac B.V.'s share price to reach $66.50 in the next year. This suggests a possible upside of 48.9% from the stock's current price. View analysts' price targets for CureVac B.V.. Who are some of CureVac B.V.'s key competitors? Some companies that are related to CureVac B.V. include Takeda Pharmaceutical (TKPYY), ASTELLAS PHARMA/ADR (ALPMY), Beigene (BGNE), Alexion Pharmaceuticals (ALXN), Shiseido (SSDOY), Genmab A/S (GMAB), UCB (UCBJF), Genmab A/S (GNMSF), Merck KGaA (MKGAF), Ono Pharmaceutical (OPHLF), Horizon Therapeutics (HZNP), Alnylam Pharmaceuticals (ALNY), Royalty Pharma (RPRX), BioMarin Pharmaceutical (BMRN) and Catalent (CTLT). View all competitors. What other stocks do shareholders of CureVac B.V. own? Based on aggregate information from My MarketBeat watchlists, some companies that other CureVac B.V. investors own include Inovio Pharmaceuticals (INO), Moderna (MRNA), Novavax (NVAX), Gilead Sciences (GILD), Pfizer (PFE), AstraZeneca (AZN), Vaxart (VXRT), Johnson & Johnson (JNJ), Rocket Companies (RKT) and Tesla (TSLA). When did CureVac B.V. IPO? (CVAC) raised $200 million in an initial public offering (IPO) on Friday, August 14th 2020. The company issued 13,300,000 shares at $14.00-$16.00 per share. BofA Securities, Jefferies and Credit Suisse served as the underwriters for the IPO and Berenberg and Kempen were co-managers. What is CureVac B.V.'s stock symbol? CureVac B.V. trades on the NASDAQ under the ticker symbol "CVAC." When did the company's quiet period expire? CureVac B.V.'s quiet period expired on Wednesday, September 23rd. CureVac B.V. had issued 13,333,333 shares in its IPO on August 14th. The total size of the offering was $213,333,328 based on an initial share price of $16.00. During the company's quiet period, underwriters and any insiders that worked on the IPO were restricted from issuing any earnings forecasts or research reports for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company. How do I buy shares of CureVac B.V.? Shares of CVAC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is CureVac B.V.'s stock price today? One share of CVAC stock can currently be purchased for approximately $44.65. How big of a company is CureVac B.V.? CureVac B.V. has a market capitalization of $7.86 billion. What is CureVac B.V.'s official website? The official website for CureVac B.V. is www.curevac.com. How can I contact CureVac B.V.? CureVac B.V.'s mailing address is PAUL-EHRLICH-STRABE 15 TUBINGEN, BADEN-WURTTEMBERG 2M, 72076. The company can be reached via phone at 49-70-71988-30 or via email at [email protected] This page was last updated on 9/25/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
